|
1
|
Allan JM and Travis LB: Mechanisms of
therapy-related carcinogenesis. Nat Rev Cancer. 5:943–955. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Seedhouse C and Russell N: Advances in the
understanding of susceptibility to treatment-related acute myeloid
leukaemia. Br J Haematol. 137:513–529. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Steinberg MH, Geary CG and Crosby WH:
Acute granulocytic leukemia complicating Hodgkin's disease. Arch
Intern Med. 125:496–498. 1970. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vardiman JW, Thiele J, Arber DA, Brunning
RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM,
Hellström-Lindberg E, Tefferi A and Bloomfield CD: The 2008
revision of the World Health Organization (WHO) classification of
myeloid neoplasms and acute leukemia: rationale and important
changes. Blood. 114:937–951. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ellis NA, Huo D, Yildiz O, Worrillow LJ,
Banerjee M, Le Beau MM, Larson RA, Allan JM and Onel K: MDM2 SNP309
and TP53 Arg72Pro interact to alter therapy-related acute myeloid
leukemia susceptibility. Blood. 112:741–749. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sabattini E, Bacci F, Sagramoso C and
Pileri SA: WHO classification of tumours of haematopoietic and
lymphoid tissues in 2008: An overview. Pathologica. 102:83–87.
2010.PubMed/NCBI
|
|
7
|
Huh HJ, Lee SH, Yoo KH, Sung KW, Koo HH,
Kim K, Jang JH, Jung C, Kim SH and Kim HJ: Therapy-related myeloid
neoplasms in 39 Korean patients: A single institution experience.
Ann Lab Med. 33:97–104. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schoch C, Kern W, Schnittger S, Hiddemann
W and Haferlach T: Karyotype is an independent prognostic parameter
in therapy-related acute myeloid leukemia (t-AML): An analysis of
93 patients with t-AML in comparison to 1091 patients with de
novo AML. Leukemia. 18:120–125. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bennett JM, Catovsky D, Daniel MT,
Flandrin G, Galton DA, Gralnick HR and Sultan C: Proposed revised
criteria for the classification of acute myeloid leukemia. A report
of the French-American-British Cooperative Group. Ann Intern Med.
103:620–625. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kayser S, Döhner K, Krauter J, Köhne CH,
Horst HA, Held G, von Lilienfeld-Toal M, Wilhelm S, Kündgen A,
Götze K, et al: German-Austrian AMLSG: The impact of
therapy-related acute myeloid leukemia (AML) on outcome in 2853
adult patients with newly diagnosed AML. Blood. 117:2137–2145.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Smith SM, Le Beau MM, Huo D, Karrison T,
Sobecks RM, Anastasi J, Vardiman JW, Rowley JD and Larson RA:
Clinical-cytogenetic associations in 306 patients with
therapy-related myelodysplasia and myeloid leukemia: the University
of Chicago series. Blood. 102:43–52. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Perera FP: Environment and cancer: who are
susceptible? Science. 278:1068–1073. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Park DJ and Koeffler HP: Therapy-related
myelodysplastic syndromes. Semin Hematol. 33:256–273.
1996.PubMed/NCBI
|
|
14
|
Pagana L, Pulsoni A, Tosti ME, Avvisati G,
Mele L, Mele M, Martino B, Visani G, Cerri R, Di Bona E, et al:
Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto: Clinical
and biological features of acute myeloid leukaemia occurring as
second malignancy: GIMEMA archive of adult acute leukaemia. Br J
Haematol. 112:109–117. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hake CR, Graubert TA and Fenske TS: Does
autologous transplantation directly increase the risk of secondary
leukemia in lymphoma patients? Bone Marrow Transplant. 39:59–70.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bloomfield CD, Archer KJ, Mrózek K,
Lillington DM, Kaneko Y, Head DR, Dal Cin P and Raimondi SC: 11q23
balanced chromosome aberrations in treatment-related
myelodysplastic syndromes and acute leukemia: Report from an
international workshop. Genes Chromosomes Cancer. 33:362–378. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Le Beau MM, Albain KS, Larson RA, Vardiman
JW, Davis EM, Blough RR, Golomb HM and Rowley JD: Clinical and
cytogenetic correlations in 63 patients with therapy-related
myelodysplastic syndromes and acute nonlymphocytic leukemia:
Further evidence for characteristic abnormalities of chromosomes.
(5 and 7)J Clin Oncol. 4:325–345. 1986.PubMed/NCBI
|
|
18
|
Uppal GK, Leighton J, Da Costa D,
Czulewicz A and Palazzo IE: Therapy related acute myeloid leukemia
with t(10:16): A rare entity. Hematol Rep. 3:e232011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pedersen-Bjergaard J: Insights into
leukemogenesis from therapy-related leukemia. N Engl J Med.
352:1591–1594. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pedersen-Bjergaard J, Specht L, Larsen SO,
Ersbøll J, Struck J, Hansen MM, Hansen HH and Nissen NI: Risk of
therapy-related leukaemia and preleukaemia after Hodgkin's disease.
Relation to age, cumulative dose of alkylating agents, and time
from chemotherapy. Lancet. 2:83–88. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Godley LA and Larson RA: Therapy-related
myeloid leukemia. Semin Oncol. 35:418–429. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Borthakur G and Estey AE: Therapy-related
acute myelogenous leukemia and myelodysplastic syndrome. Curr Oncol
Rep. 9:373–377. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Micallef IN, Lillington DM, Apostolidis J,
Amess JA, Neat M, Matthews J, Clark T, Foran JM, Salam A, Lister TA
and Rohatiner AZ: Therapy-related myelodysplasia and secondary
acute myelogenous leukemia after high-dose therapy with autologous
hematopoietic progenitor-cell support for lymphoid malignancies. J
Clin Oncol. 18:947–955. 2000.PubMed/NCBI
|
|
24
|
Lillington DM, Micallef IN, Carpenter E,
Neat MJ, Amess JA, Matthews J, Foot NJ, Young BD, Lister TA and
Rohatiner AZ: Detection of chromosome abnormalities pre-high-dose
treatment in patients developing therapy-related myelodysplasia and
secondary acute myelogenous leukemia after treatment for
non-Hodgkin's lymphoma. J Clin Oncol. 19:2472–2481. 2001.PubMed/NCBI
|
|
25
|
Leone G, Pagano L, Ben-Yehuda D and Voso
MT: Therapy-related leukemia and myelodysplasia: Susceptibility and
incidence. Haematologica. 92:1389–1398. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Armitage JO, Carbone PP, Connors JM,
Levine A, Bennett JM and Kroll S: Treatment-related myelodysplasia
and acute leukemia in non-Hodgkin's lymphoma patients. J Clin
Oncol. 21:897–906. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Milligan DW Ruiz, De Elvira MC, Kolb HJ,
Goldstone AH, Meloni G, Rohatiner AZ, Colombat P and Schmitz N:
European Group for Blood and Marrow Transplantation: Secondary
leukaemia and myelodysplasia after autografting for lymphoma:
Results from the EBMT. EBMT Lymphoma and Late Effects Working
Parties. European Group for Blood and Marrow Transplantation. Br J
Haematol. 106:1020–1026. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Darrington DL, Vose JM, Anderson JR,
Bierman PJ, Bishop MR, Chan WC, Morris ME, Reed EC, Sanger WG and
Tarantolo SR: Incidence and characterization of secondary
myelodysplastic syndrome and acute myelogenous leukemia following
high-dose chemoradiotherapy and autologous stem-cell
transplantation for lymphoid malignancies. J Clin Oncol.
12:2527–2534. 1994.PubMed/NCBI
|
|
29
|
Metayer C, Curtis RE, Vose J, Sobocinski
KA, Horowitz MM, Bhatia S, Fay JW, Freytes CO, Goldstein SC, Herzig
RH, et al: Myelodysplastic syndrome and acute myeloid leukemia
after autotransplantation for lymphoma: A multicenter case-control
study. Blood. 101:2015–2023. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Brown JR, Yeckes H, Friedberg JW, Neuberg
D, Kim H, Nadler LM and Freedman AS: Increasing incidence of late
second malignancies after conditioning with cyclophosphamide and
total-body irradiation and autologous bone marrow transplantation
for non-Hodgkin's lymphoma. J Clin Oncol. 23:2208–2214. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Stone RM, Neuberg D, Soiffer R, Takvorian
T, Whelan M, Rabinowe SN, Aster JC, Leavitt P, Mauch P and Freedman
AS: Myelodysplastic syndrome as a late complication following
autologous bone marrow transplantation for non-Hodgkin's lymphoma.
J Clin Oncol. 12:2535–2542. 1994.PubMed/NCBI
|
|
32
|
Lenz G, Dreyling M, Schiegnitz E,
Haferlach T, Hasford J, Unterhalt M and Hiddemann W: Moderate
increase of secondary hematologic malignancies after myeloablative
radiochemotherapy and autologous stem-cell transplantation in
patients with indolent lymphoma: Results of a prospective
randomized trial of the German Low Grade Lymphoma Study Group. J
Clin Oncol. 22:4926–4933. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pulsoni A, Pagano L, Lo Coco F, Avvisati
G, Mele L, Di Bona E, Invernizzi R, Leoni F, Marmont F, Mele A, et
al: Clinicobiological features and outcome of acute promyelocytic
leukemia occurring as a second tumor: The GIMEMA experience. Blood.
100:1972–1976. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mrózek K, Heerema NA and Bloomfield CD:
Cytogenetics in acute leukemia. Blood Rev. 18:115–136. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Schlenk RF and Döhner K: Impact of new
prognostic markers in treatment decisions in acute myeloid
leukemia. Curr Opin Hematol. 16:98–104. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kalaycio M, Rybicki L, Pohlman B, Sobecks
R, Andresen S, Kuczkowski E and Bolwell B: Risk factors before
autologous stem-cell transplantation for lymphoma predict for
secondary myelodysplasia and acute myelogenous leukemia. J Clin
Oncol. 24:3604–3610. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Eichenauer DA and Engert A:
Therapy-related myeloid neoplasms in patients treated for Hodgkin's
lymphoma. Mediterr J Hematol Infect Dis. 3:e20110462011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ogami A, Morimoto A, Hibi S, Todo S,
Sugimoto T, Mori K, Imamura T, Ishida H, Yoshihara T, Iguchi A, et
al: Secondary acute promyelocytic leukemia following chemotherapy
for non-Hodgkin's lymphoma in a child. J Pediatr Hematol Oncol.
26:427–430. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yuan SZ and Su H: Clinical translational
research of chimeric antigen receptor-T (CAR-T) cells for the
treatment of relapsed and refractory B-cell lymphoma/leukemia.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 22:1137–1141. 2014.(In
Chinese). PubMed/NCBI
|
|
40
|
Wang QS, Wang Y, Lv HY, Han QW, Fan H, Guo
B, Wang LL and Han WD: Treatment of CD33-directed chimeric antigen
receptor-modified T cells in one patient with relapsed and
refractory acute myeloid leukemia. Mol Ther. 23:184–191. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
DeFrancesco L: CAR-T cell therapy seeks
strategies to harness cytokine storm. Nat Biotechnol. 32:6042014.
View Article : Google Scholar : PubMed/NCBI
|
